Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
77.42
-0.22 (-0.28%)
May 30, 2025, 10:40 AM - Market open
Corcept Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Corcept Therapeutics stock ranges from a low of $131 to a high of $150. The average analyst price target of $142 forecasts a 83.42% increase in the stock price over the next year.
Price Target: $142.00 (+83.42%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Corcept Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $150 → $145 | Strong Buy | Maintains | $150 → $145 | +87.29% | May 6, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $128 → $131 | Buy | Maintains | $128 → $131 | +69.21% | Apr 3, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $130 → $142 | Strong Buy | Maintains | $130 → $142 | +83.42% | Apr 1, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $76 → $150 | Strong Buy | Maintains | $76 → $150 | +93.75% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $115 → $150 | Strong Buy | Maintains | $115 → $150 | +93.75% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
917.03M
from 675.04M
Increased by 35.85%
Revenue Next Year
1.24B
from 917.03M
Increased by 35.22%
EPS This Year
1.41
from 1.23
Increased by 14.23%
EPS Next Year
2.71
from 1.41
Increased by 93.10%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 946.4M | 1.5B | 2.1B | ||
| Avg | 917.0M | 1.2B | 1.6B | ||
| Low | 876.3M | 1.0B | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.2% | 58.2% | 69.4% | ||
| Avg | 35.8% | 35.2% | 32.4% | ||
| Low | 29.8% | 10.2% | -10.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.60 | 4.16 | 7.70 | ||
| Avg | 1.41 | 2.71 | 6.11 | ||
| Low | 1.24 | 1.10 | 3.65 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 29.8% | 195.9% | 183.7% | ||
| Avg | 14.2% | 93.1% | 125.1% | ||
| Low | 1.2% | -21.9% | 34.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.